United Kingdom· GB-APID-35363311000001106
Rydapt 25mg capsules
A midostaurin product containing midostaurin, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Midostaurin is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EX10 (midostaurin), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Midostaurin · ATC L01EX10
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Midostaurin
- Manufacturer
- Novartis Pharmaceuticals UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01EX10
- ATC class
- Midostaurin
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 3
- gtin5010678918212
- gtin7613421024369
- gtin7613421057657
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
582 interactions on record for midostaurin.
Graded by severity as the source publishes them — 132 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Midostaurin · interactions on record
582 records
- 132 severe
- 445 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Midostaurin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaRYDAPTNOVARTIS PHARMACEUTICALS CANADA INC
- NetherlandsRydapt 25 mg, zachte capsuleNovartis Europharm Limited
- FinlandRydaptOrifarm Oy
- SwitzerlandRydapt 25 mg, WeichkapselnNovartis Pharma Schweiz AG
- CzechiaRYDAPTNovartis Europharm Limited, Dublin
- United StatesRYDAPTNovartis Pharmaceuticals Corporation
- BelgiumRydapt 25 mgNovartis Europharm
- IcelandRydaptNovartis Europharm Limited*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rydapt
- Liechtenstein · Rydapt
- Norway · Rydapt
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc0d3585-7f77-4d51-9273-d468ce9e470b GET /v1/drugs/dc0d3585-7f77-4d51-9273-d468ce9e470b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "35363311000001106",
"desc": "Rydapt 25mg capsules (Novartis Pharmaceuticals UK Ltd)",
"form": "Oral capsule",
"vpid": "35385211000001102",
"source": "dmd",
"vtm_id": "776788009",
"strength": "25 mg",
"substance": "Midostaurin",
"ingredient": "Midostaurin",
"supplier_code": "2920101000001102"
}See everything about midostaurin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.